# MONTHLY MEDICATION SAFETY UPDATE

## Information for health professionals in NSW public health organisations

This is a summary of medication safety and supply related issues affecting NSW public health facilities in **July 2023**. Updates regarding current medication-specific safety and supply related issues are available on the <u>CEC website</u>.

### Medication safety issues under investigation

- Assessment regarding suitability of adding andexanet alfa to the NSW Medicines Formulary currently underway.
- Disruption to the supply of glucagon (GlucaGen Hypokit) - Safety Notice being prepared.

#### Relevant clinician information to note

- Statewide consultation regarding revised High-Risk Medicines Management Policy Directive and associated Standards has begun - 'Have your say' here.
- TGA updates:
  - Ryzodeg 70/30 FlexTouch insulin prefilled pens <u>shortage</u> – a <u>Serious Scarcity</u> <u>Substitution Instrument (SSSI)</u> has been issued
  - Ozempic (semaglutide) <u>shortage extension</u> <u>and change to prescribing advice</u>
  - Ordine (morphine) oral liquid <u>discontinuation</u>
  - o Trulicity (dulaglutide) shortage extension
  - MS-2 Step (mifepristone and misoprostol) amendments to prescribing restrictions
  - COVID-19 vaccine <u>safety report</u> and <u>ICMRA</u> statement
  - MDMA and psilocybin <u>updates to access</u> and safeguards
  - Product Information safety updates June 2023

#### Current projects with eHealthNSW

- Continued collaboration on the VTE Prevention eMR project, working towards a pilot beginning in October this year.
- Continued collaboration on the NSW Medicines Formulary online platform.

### **Medication Safety and Supply Summary**

14	SAFETY/SUPPLY ISSUES
	MADE APPARENT TO CEC
5	OF THESE REQUIRED FURTHER
	INVESTIGATION DUE TO
	POTENTIAL SAFETY CONCERNS
7	WERE REPORTED TO FRONTLINE DUE
	TO SAFETY RISK REQUIRING LOCAL
	MITIGATION
2	RESULTED IN FORMAL SAFETY
	COMMUNICATION
1	PREVIOUS ISSUES RESOLVED ON CEC
	ONLINE PORTAL

### Safety Alerts/Notices/Information released

SN:017/23: Intravenous and subcutaneous Immunoglobulins (IVIg and SCIg): Potential for error: look-alike / sound-alike – 27 July 2023

#### **Medication Safety Communications released**

Insulin degludec 70% with insulin aspart 30 % (Ryzodeg® 70/30 FlexTouch®) pre-filled pens – originally published on 19 July; updated and republished on 2 August 2023

# Medications reported on online portal this month

Dipyridamole (Persantin) 10 mg/2 mL, glucagon (GlucaGen) Hypokit, methylprednisolone sodium succinate injection, morphine hydrochloride (Ordine) oral solution, Ryzodeg 70/30 FlexTouch, semaglutide, vigabatrin 500 mg sachets and tablets

#### **Contact us**

If you need support or assistance with medication safety matters in your facility, please email us <a href="mailto:CEC-MedicationSafety@health.nsw">CEC-MedicationSafety@health.nsw</a>, gov.au.



